Table. Quinolone susceptibility of 499 Salmonella isolates collected from travelers returning to Finland, by country visited, 2003−2007*.
| Country visited | No. (%) isolates | No. isolates with CIP MIC >0.125 µg/mL | No. isolates with NAL MIC >32 µg/mL | No. isolates with NAL MIC <32 µg/mL | No. trips from Finland during study months† |
|---|---|---|---|---|---|
| Thailand‡ | 212 (42.5) | 98 | 67 | 31 | 122,472 |
| Spain§ | 66 (13.2) | 25 | 25 | 0 | 426,822 |
| Brazil | 41 (8.2) | 0 | 0 | 0 | 25,009 |
| Egypt | 40 (8.0) | 17 | 17 | 0 | 47,291 |
| India | 32 (6.4) | 7 | 7 | 0 | 26,233 |
| Malaysia | 15 (3.0) | 6 | 1 | 5 | 2,597 |
| Vietnam | 9 (1.8) | 2 | 2 | 0 | 7,555 |
| Tanzania | 9 (1.8) | 2 | 2 | 0 | 1,259 |
| Portugal | 8 (1.6) | 7 | 7 | 0 | 35,899 |
| Morocco | 5 (1.0) | 3 | 3 | 0 | 8,708 |
| Other areas |
62 (12.4) |
14 |
14 |
0 |
|
| Total | 499 (100) | 181 | 145 | 36 |
*CIP, ciprofloxacin; NAL, nalidixic acid. †Data collected from statistics reports, Finland, based on the no. of Finnish travelers to these countries. ‡No. Finnish travelers to Thailand from 2003 to 2007: 21,873; 22,882; 17,661; 21,941; and 38,115, respectively. §Includes Canary Islands.